miR-185 is an independent prognosis factor and suppresses tumor metastasis in gastric cancer

Abstract

miR-185 has been identified as an important factor in several cancers such as breast cancer, ovarial cancer, and prostate cancer. However, its effect and prognostic value in gastric cancer are still poorly known. In this study, we found that the expression levels of miR-185 were strongly downregulated in gastric cancer and associated with clinical stage and the presence of lymph node metastases. Moreover, miR-185 might independently predict OS and RFS in gastric cancer. We further found that upregulation of miR-185 inhibited the proliferation and metastasis of gastric cancer cells in vitro and in vivo. Taken together, our findings demonstrate that the miR-185 is important for gastric cancer initiation and progression and holds promise as a prognostic biomarker to predict survival and relapse in gastric cancer. It is also a potential therapeutic tool to improve clinical outcomes in the above disease.

Gastric adenocarcinoma microRNA profiles in fixed tissue and in plasma reveal cancer-associated and Epstein-Barr virus-related expression patterns

“…All four of these microRNAs have been described as being dysregulated in gastric cancer tissue or plasma, and hsa-miR-155 is known to be induced by EBV. 21,44,45,47,48,73,74,82,83 Hsa-miR-200a was previously reported to be downregulated by EBV, 84 and we observed this same trend, but this association did not reach significance following Bonferroni correction. Nevertheless, the unique pattern of human microRNA dysregulation seen in association with EBV infection suggests that the virus is not an innocent bystander when it is present within malignant cells.…”

Prognostic role of microRNAs in human gastrointestinal cancer: A systematic review and meta-analysis

“…Cut-off values of high or low miRs expression were mainly mean and median values. As for clinical endpoints, there were 46 studies [1, 2, 10–12, 16, 20, 22, 24–27, 29–33, 36–41, 43–59, 61–66] including overall survival (OS), 5 studies [67–71] including disease free survival (DFS) and another 9 studies [18, 19, 21, 23, 28, 34, 35, 42, 60] including both OS and DFS. We have identified a total of 59 miRs including 23 significantly up-regulated expression miRs (miR-214, miR-17, miR-20a, miR-200c, miR-107, miR-27a, miR-196b, miR-222, miR-106b, miR-500, miR-377, miR-25, miR-181a, miR-183, miR-1288, miR-106a-5p, miR-21, miR-30e, miR-142-3p, miR-1246, miR-508, miR-503, miR-942) and 36 significantly down-regulated expression miRs (miR-433, let-7g, miR-125a-5p, miR-760, miR-206, miR-26a, miR-200b, miR-185, miR-22, miR-217, miR-506, miR-133, miR-218, miR-137, miR-326, miR-486-5p, miR-29, miR-23b-3p, miR-194, miR-451, miR-34a, miR-106a, miR-143, miR-16, miR-139-3p, miR-361-5p, miR-365, miR-338-3p, miR-200c, miR-141, miR-150, miR-138, miR-134a, miR-195, miR-203, miR-375) correlated with poor prognosis in GIC patients (Table 1, Table 2).…”

miR-326-Histone Deacetylase-3 Feedback Loop Regulates the Invasion and Tumorigenic and Angiogenic Response to Anti-cancer Drugs

“…miRNA databases predict that both HDAC3 and p53 are regulated by miR-326 and miR-185 (data not shown). miR-185 acts as a tumor suppressor and suppresses gastric cancer metastasis (32). However, miRNA array shows no difference in the expression of miR-185 in between Malme3M and Malme3M R cells (data not shown).…”